Information Provided By: 
Fly News Breaks for November 19, 2015
MYGN
Nov 19, 2015 | 07:19 EDT
Stephens analyst Drew Jones said the CMS decision to use gap fill pricing for Vectra for 2016 is a big positive for Myriad Genetics, since cross walk pricing would have led to an about 60% reduction to this year's rate. The analyst, who views Vectra as the next key growth driver for Myriad , keeps an Overweight rating and $47 price target on the shares.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
